2022
Electroencephalographic changes in purified pharmaceutical cannabidiol therapy
Herlopian A, Barnett JR, Nascimento FA, Lee H, Thiele EA. Electroencephalographic changes in purified pharmaceutical cannabidiol therapy. Epilepsy & Behavior 2022, 128: 108558. PMID: 35078115, DOI: 10.1016/j.yebeh.2022.108558.Peer-Reviewed Original ResearchConceptsInterictal epileptiform dischargesElectroencephalographic changesCBD treatmentIctal findingsSleep architectureEEG changesInvestigational New Drug programPredominant seizure typeNew drug programPre-treatment EEGYears of ageSubjective cognitive improvementElectrographic findingsElectrographic improvementRefractory epilepsySeizure typesClinical outcomesElectrographic changesEpileptiform dischargesPatientsCognitive improvementDrug programsSubstantial associationEEG studiesTreatment
2020
Cannabidiol in treatment of refractory epileptic spasms: An open-label study
Herlopian A, Hess EJ, Barnett J, Geffrey AL, Pollack SF, Skirvin L, Bruno P, Sourbron J, Thiele EA. Cannabidiol in treatment of refractory epileptic spasms: An open-label study. Epilepsy & Behavior 2020, 106: 106988. PMID: 32169600, DOI: 10.1016/j.yebeh.2020.106988.Peer-Reviewed Original ResearchConceptsRefractory epileptic spasmsEpileptic spasmsResponder rateAdjunctive therapyCBD treatmentInvestigational new drug trialsOpen-label studyMonths of treatmentSafe adjunctive therapyNew drug trialsInstitutional review boardSubjective reportsBaseline medicationsCBD initiationElectrographic findingsHypsarrhythmia patternClinical responseSeizure frequencyAdverse eventsClinical efficacyElectrographic changesSubjective improvementTarget dosageDrug trialsInitial dosage
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply